The United States Food and Drug Administration (USFDA) has conducted a pre-approval and cGMP inspection covering commercial manufacturing activities for the US market at Syngene International’s Bengaluru facilities. The inspection conducted from February 10, 2025 to February 20, 2025. On conclusion of the inspection, the USFDA issued Form 483 with 5 observations. The Company will work closely with USFDA and remains committed to addressing these observations comprehensively within the stipulated time.
Syngene International is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide.
| Company Name | CMP |
|---|---|
| Syngene Internation. | 440.40 |
| Indegene | 517.40 |
| CMS Info Systems | 294.40 |
| JITF Infralogistics | 299.95 |
| Sagility | 39.83 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: